Treatment outcomes following Cyberknife radiosurgery for refractory Trigeminal Neuralgia.
PD-0248
Abstract
Treatment outcomes following Cyberknife radiosurgery for refractory Trigeminal Neuralgia.
Authors: Marina Amorim1, Catarina Silva1, Maria Adelina Costa2, Graça Fonseca2, Cármen Calçada2, João Conde2, Osvaldo Carvalhosa1, Sofia Ramos1, Joana Vale2, Ana Cavaco2, Pedro Vieira2, Paula Genésio2, Paulo Costa2,1
1Hospital de Braga, Radiation Oncology, Braga, Portugal; 2Instituto CUF - Júlio Teixeira S.A. , Radiation Oncology, Porto, Portugal
Show Affiliations
Hide Affiliations
Purpose or Objective
Trigeminal
Neuralgia (TN) is a debilitating condition characterized by agonizing,
paroxysmal, and lancinating pain. TN is also called “suicide disease”,
terminology denoting the pain extent of these patients. Cyberknife®
radiosurgery (CKRS) consists of a radiotherapy non-invasive image-guided
procedure. Our propose is to evaluate the effectiveness and safety of CKRS for
medically and surgically intractable TN.
Material and Methods
We retrospectively evaluated 15 patients (3 male and 12 female) with
recurrent TN submitted to CKRS between March 2016 and June 2021, at our
institution (9 with left, 5 with right and 1 with bilateral TN). Patients
received CKRS with a mean dose of 70 Gy applied to an average 77% isodose line on
the affected trigeminal nerve. The final plan was developed according to the individual
anatomy and dose distribution over the trigeminal nerve and maximum dose on the brainstem. Trigeminal pain and hypoesthesia were classified according to the
Barrow Neurological Institute (BNI).
Results
Median age was 68 (44-81) years old. Before
radiosurgery, all patients reported uncontrolled/recurrent pain with
medication, being carbamazepine and pregabalin the most common drugs used. The
median follow-up was 36,5 months (4-67). Median target volume was 0,08 cm³
(0,05-0,21) and median normalized conformity index was 1,83 (1,34-2,71).
One patient had TN secondary to multiple sclerosis. One patient had been previously
submitted to surgery and one had undergone CKRS one year before. All the
patients reported pain relief within the first 3 months after CKRS treatment. The
majority (62%) were free of antalgic medication (BNI I/II) for a median period
of 34 months (1-64 months). In the last follow-up, 38% of the patients reported
controlled pain with medication (BNI III) and we haven’t observed cases of
inadequately controlled or severe pain (BNI IV-V). Most of the patients (72%) didn’t
report facial numbness after CKRS. We observed facial hypoesthesia in 28% of
the patients, half of them presented with bothersome facial numbness (BNI IV).
Conclusion
Frameless image-guided
robotic radiosurgery in experienced hands is a safe and effective procedure for
the treatment of TN, providing excellent pain control rates in absence of major
neurological complications. Even patients with severely debilitating symptoms
may experience significant and sustained pain relief after CKRS. Thus, it
should be considered as a viable alternative to more invasive treatments for
this painful condition, with a real impact on the quality of life of these
patients.